Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock, par value $.001
-
Shares outstanding
-
65,833,370
-
Number of holders
-
63
-
Total 13F shares, excl. options
-
27,786,246
-
Shares change
-
+23,817,439
-
Total reported value, excl. options
-
$361,216,517
-
Value change
-
+$310,785,532
-
Put/Call ratio
-
27%
-
Number of buys
-
47
-
Number of sells
-
-13
-
Price
-
$13.00
Significant Holders of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) as of Q2 2020
80 filings reported holding CLDX - Celldex Therapeutics, Inc. - Common Stock, par value $.001 as of Q2 2020.
Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) has 63 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 27,786,246 shares
of 65,833,370 outstanding shares and own 42% of the company stock.
Largest 10 shareholders include BVF INC/IL (2,740,000 shares), RTW INVESTMENTS, LP (2,610,000 shares), Redmile Group, LLC (2,000,000 shares), Logos Global Management LP (2,000,000 shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1,750,000 shares), Ikarian Capital, LLC (1,647,439 shares), RENAISSANCE TECHNOLOGIES LLC (1,637,175 shares), Vivo Capital, LLC (1,600,000 shares), VANGUARD GROUP INC (1,296,206 shares), and RA CAPITAL MANAGEMENT, L.P. (1,150,000 shares).
This table shows the top 63 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.